FIELD: medicine.
SUBSTANCE: present invention refers to compounds for treating viral hepatitis of formula: , wherein R1, R2 and R3 are independently specified in hydrogen and C1-6alkylcarbonyl; provided at least one of R1, R2 and R3 are different from hydrogen, and provided a compound according to formula I is other than (2R,3R,4S,5R)-4-acetoxy-5-acetoxymethyl-5-azido-2-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-3-yl ester of acetic acid, as well as to their pharmaceutically acceptable salts and based pharmaceutical compositions.
EFFECT: there are presented new effective agents for treating hepatitis C virus infection.
12 cl, 9 ex, 8 dwg
Title | Year | Author | Number |
---|---|---|---|
ANTIVIRAL HETEROCYCLIC COMPOUNDS | 2011 |
|
RU2572558C2 |
PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDES | 2010 |
|
RU2553656C2 |
DERIVATIVES OF (4-METHYLSULPHONYLAMINOPHENYL)-QUINOLINE, USEFUL IN TREATMENT OF HEPATITIS C | 2011 |
|
RU2572835C2 |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTION | 2006 |
|
RU2440822C2 |
MACROCYCLIC INDOLE DERIVATIVES, APPLICABLE AS INHIBITORS OF HEPATITIS C VIRUS | 2009 |
|
RU2518471C2 |
BIS-BENZIMIDAZOLE DERIVATIVES AS HEPATITIS C VIRUS INHIBITORS | 2010 |
|
RU2540897C2 |
ANTIVIRAL NUCLEOSIDES | 2006 |
|
RU2422454C2 |
2-AMIDO-4-ARYLOXY-1-CARBONYLPYRROLIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS, PARTICULARLY NS3-NS4A HCV PROTEASE | 2004 |
|
RU2440368C2 |
NUCLEOSIDE INHIBITORS OF RNA-POLYMERASE HCV NS5B, METHODS FOR PRODUCTION AND USE THEREOF | 2014 |
|
RU2567854C1 |
MACROCYCLIC HEPATITIS C INHIBITORS | 2006 |
|
RU2436787C2 |
Authors
Dates
2015-07-20—Published
2011-01-25—Filed